Erasca Partners with Novartis for the Development of Naporafenib Combinations in a Series of SEACRAFT Studies to Treat Solid Tumors
Shots:
- Erasca has signed two clinical trial collaboration and supply agreements (CTCSAs) with Novartis to develop the combination of naporafenib (pan-RAF inhibitor) and Mekinist (trametinib) in a series of SEACRAFT trials for the treatment of solid tumors
- As per the agreements, Erasca will sponsor the P-Ib (SEACRAFT-1) and P-III (SEACRAFT-2) studies to investigate naporafenib + Mekinist for the treatment of RAS Q61X solid tumors and previously treated NRASm unresectable/metastatic melanoma, respectively. Mekinist will be provided by Novartis at zero cost
- Moreover, the company anticipates initial P-Ib (SEACRAFT-1) trial results b/w Q2’24-Q4’24 and commencement of the P-III (SEACRAFT-2) study in H1’24
Ref: Erasca | Image: Erasca
Related News:- Novartis Entered into an Exclusive Worldwide License Agreement with Erasca for Naporafenib
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
